Heptapeptide HP3 acts as a potent inhibitor of experimental imiquimod‑induced murine psoriasis and impedes the trans‑endothelial migration of mononuclear cells

Vázquez‑Sánchez,Ernesto   A.; Mendoza‑Figueroa,José  S.; Gutiérrez‑Gonzalez,Guadalupe; Zapi‑Colín,Luis   A.; Torales‑Cardeña,Azael; Briseño‑Lugo,Paola   E.; Díaz‑Toalá,Iván; Cancino‑Diaz,Juan   C.; Pérez‑Tapia,Sonia   M.; Cancino‑Diaz,Mario   E.; Gómez‑Chávez,Fernando; Rodríguez‑Martínez,Sandra

doi:10.3892/mmr.2020.11128

Heptapeptide HP3 acts as a potent inhibitor of experimental imiquimod‑induced murine psoriasis and impedes the trans‑endothelial migration of mononuclear cells

Authors:
- Ernesto A. Vázquez‑Sánchez
- José S. Mendoza‑Figueroa
- Guadalupe Gutiérrez‑Gonzalez
- Luis A. Zapi‑Colín
- Azael Torales‑Cardeña
- Paola E. Briseño‑Lugo
- Iván Díaz‑Toalá
- Juan C. Cancino‑Diaz
- Sonia M. Pérez‑Tapia
- Mario E. Cancino‑Diaz
- Fernando Gómez‑Chávez
- Sandra Rodríguez‑Martínez
View Affiliations

Affiliations: Laboratory of Innate Immunology, Department of Immunology, Escuela Nacional de Ciencias Biológicas (ENCB)‑Instituto Politécnico Nacional (IPN), Mexico City 11340, Mexico, Department of Physics‑Chemistry and Biology, Linköping University, 581 83 Linköping, Sweden, Department of Disciplinary Basic Formation, Escuela Nacional de Medicina y Homeopatía (ENMyH)‑IPN, Mexico City 07320, Mexico, Department of Biological Sciences, Health Science Section, Facultad de Estudios Superiores Cuautitlán, Universidad Nacional Autónoma de México (UNAM), Mexico City 54740, Mexico, Department of Computational Systems Engineering, Escuela Superior de Cómputo‑IPN, México City 07738, Mexico, Laboratory of Immunomicrobiology, Department of Microbiology, ENCB‑IPN, Mexico City 11340, Mexico, National Laboratory for Specialized Services for Research, Development and Innovation for Pharmacochemistry and Biotechnology products, ENCB‑IPN, Mexico City 11340, Mexico
Published online on: May 5, 2020 https://doi.org/10.3892/mmr.2020.11128
Pages: 507-515
Copyright: © Vázquez‑Sánchez et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

During the progression of psoriatic lesions, abundant cellular infiltration of myeloid cells, such as macrophages and activated dendritic cells, occurs in the skin and the infiltrating cells interact with naive lymphoid cells to generate a T helper (Th)1 and Th17 environment. Therapies to treat psoriasis include phototherapy, non‑steroidal and steroidal drugs, as well as antibodies to block tumor necrosis factor‑α, interleukin (IL)‑17‑A and IL‑12/IL‑23, which all focus on decreasing the proinflammatory hallmark of psoriasis. The present study obtained the heptapeptide HP3 derived from phage display technology that blocks mononuclear cell adhesion to endothelial cells and inhibits trans‑endothelial migration in vitro. The activity of the heptapeptide in a murine model of psoriasis was also assessed, which indicated that early administration inhibited the development of psoriatic lesions. Therefore, the results suggested that HP3 may serve as a potential therapeutic target for psoriasis.

View Figures

View References

1	Hickey MJ, Reinhardt PH, Ostrovsky L, Jones WM, Jutila MA, Payne D, Elliott J and Kubes P: Tumor necrosis factor-alpha induces leukocyte recruitment by different mechanisms in vivo and in vitro. J Immunol. 158:3391–3400. 1997.PubMed/NCBI
2	Li Q, Chandran V, Tsoi L, O'Rielly D, Nair RP, Gladman D, Elder JT and Rahman P: Quantifying differences in heritability among psoriatic arthritis (PsA), cutaneous psoriasis (PsC) and psoriasis vulgaris (PsV). Sci Rep. 10:49252020. View Article : Google Scholar : PubMed/NCBI
3	Beurskens T, Chang A, van Erp PE and van de Kerkhof PC: Epidermal proliferation and accumulation of polymorphonuclear leukocytes in the psoriatic lesion. Dermatologica. 178:67–72. 1989. View Article : Google Scholar : PubMed/NCBI
4	Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, Meyer zum Büschenfelde KH and Fleischer B: T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol. 102:145–149. 1994. View Article : Google Scholar : PubMed/NCBI
5	Nestle FO, Di Meglio P, Qin JZ and Nickoloff BJ: Skin immune sentinels in health and disease. Nat Rev Immunol. 9:679–691. 2009. View Article : Google Scholar : PubMed/NCBI
6	Singh K, Gatzka M, Peters T, Borkner L, Hainzl A, Wang H, Sindrilaru A and Scharffetter-Kochanek K: Reduced CD18 levels drive regulatory T cell conversion into Th17 cells in the CD18hypo PL/J mouse model of psoriasis. J Immunol. 190:2544–2553. 2013. View Article : Google Scholar : PubMed/NCBI
7	He Q, Chen HX, Li W, Wu Y, Chen SJ, Yue Q, Xiao M and Li JW: IL-36 cytokine expression and its relationship with p38 MAPK and NF-κB pathways in psoriasis vulgaris skin lesions. J Huazhong Univ Sci Technolog Med Sci. 33:594–599. 2013. View Article : Google Scholar : PubMed/NCBI
8	Nedoszytko B, Sokołowska-Wojdyło M, Ruckemann- Dziurdzińska K, Roszkiewicz J and Nowicki RJ: Chemokines and cytokines network in the pathogenesis of the inflammatory skin diseases: Atopic dermatitis, psoriasis and skin mastocytosis. Postepy Dermatol Alergol. 31:84–91. 2014. View Article : Google Scholar : PubMed/NCBI
9	Alexander H and Nestle FO: Pathogenesis and immunotherapy in cutaneous psoriasis. what can rheumatologists learn? Curr Opin Rheumatol. 29:71–78. 2017. View Article : Google Scholar : PubMed/NCBI
10	Guenther L, Van De Kerkhof PC, Snellman E, Kragballe K, Chu AC, Tegner E, Garcia-Diez A and Springborg J: Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: A randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol. 147:316–323. 2002. View Article : Google Scholar : PubMed/NCBI
11	Shah RA, Nwannunu CE, Limmer AL, Patel RR, Mui UN and Tyring SK: Brief update on dermatologic uses of methotrexate. Skin Therapy Lett. 24:5–8. 2019.
12	Krueger G and Callis K: Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis. Arch Dermatol. 140:218–225. 2004. View Article : Google Scholar : PubMed/NCBI
13	Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, Langley RG, de Lemos JA, Daoud Y, Blankenship D, et al: Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: A meta-analysis of randomized controlled trials. JAMA. 306:864–871. 2011. View Article : Google Scholar : PubMed/NCBI
14	Tzellos T, Kyrgidis A, Trigoni A and Zouboulis CC: Point: Major adverse cardiovascular events and anti-IL 12/23 agents. J Am Acad Dermatol. 70:380–381. 2014. View Article : Google Scholar : PubMed/NCBI
15	Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, Ziv M, Pinter A, Hugot S, You R and Milutinovic M: Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 73:400–409. 2015. View Article : Google Scholar : PubMed/NCBI
16	Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, et al: Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 375:345–356. 2016. View Article : Google Scholar : PubMed/NCBI
17	Su Z, Paulsboe S, Wetter J, Salte K, Kannan A, Mathew S, Horowitz A, Gerstein C, Namovic M, Todorović V, et al: IL-36 receptor antagonistic antibodies inhibit inflammatory responses in preclinical models of psoriasiform dermatitis. Exp Dermatol. 28:113–120. 2019. View Article : Google Scholar : PubMed/NCBI
18	Rossi B and Constantin G: Anti-selectin therapy for the treatment of inflammatory diseases. Inflamm Allergy Drug Targets. 7:85–93. 2008. View Article : Google Scholar : PubMed/NCBI
19	Rychly J and Nebe B: Therapeutic strategies in autoimmune diseases by interfering with leukocyte endothelium interaction. Curr Pharm Des. 12:3799–3806. 2006. View Article : Google Scholar : PubMed/NCBI
20	Radi ZA, Kehrli ME Jr and Ackermann MR: Cell adhesion molecules, leukocyte trafficking, and strategies to reduce leukocyte infiltration. J Vet Intern Med. 15:516–529. 2001. View Article : Google Scholar : PubMed/NCBI
21	Koo JY, Bagel J, Sweetser MT and Ticho BS: Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: Results from an open-label, multicenter study. J Drugs Dermatol. 5:623–628. 2006.PubMed/NCBI
22	van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, Cornelissen F, Mus AM, Florencia E, Prens EP and Lubberts E: Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 182:5836–5845. 2009. View Article : Google Scholar : PubMed/NCBI
23	Strober BE, Bissonnette R, Fiorentino D, Kimball AB, Naldi L, Shear NH, Goyal K, Fakharzadeh S, Calabro S, Langholff W, et al: Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study [Psoriasis Longitudinal Assessment and Registry (PSOLAR)]. J Am Acad Dermatol. 74:851–861.e4. 2016. View Article : Google Scholar : PubMed/NCBI
24	Branisteanu DE, Voicu CM, Cretu A, Dimitriu A, Luca MC and Salavastru CM: Adverse reactions of biological therapy for psoriasis. Rev Med Chir Soc Med Nat Iasi. 119:38–44. 2015.PubMed/NCBI
25	Lau JL and Dunn MK: Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg Med Chem. 26:2700–2707. 2018. View Article : Google Scholar : PubMed/NCBI